• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Toll样受体信号通路在严重急性呼吸综合征冠状病毒2诱导的固有免疫反应中的作用以及Toll样受体免疫调节剂在2019冠状病毒病患者中的潜在应用价值

Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019.

作者信息

Dai Jiayu, Wang Yibo, Wang Hongrui, Gao Ziyuan, Wang Ying, Fang Mingli, Shi Shuyou, Zhang Peng, Wang Hua, Su Yingying, Yang Ming

机构信息

Department of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun, China.

College of Clinical Medicine, Jilin University, Changchun, China.

出版信息

Front Microbiol. 2022 Jun 27;13:948770. doi: 10.3389/fmicb.2022.948770. eCollection 2022.

DOI:10.3389/fmicb.2022.948770
PMID:35832809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9271922/
Abstract

Toll-like receptors (TLRs) are key sensors that recognize the pathogen-associated molecular patterns (PAMPs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to activate innate immune response to clear the invading virus. However, dysregulated immune responses may elicit the overproduction of proinflammatory cytokines and chemokines, resulting in the enhancement of immune-mediated pathology. Therefore, a proper understanding of the interaction between SARS-CoV-2 and TLR-induced immune responses is very important for the development of effective preventive and therapeutic strategies. In this review, we discuss the recognition of SARS-CoV-2 components by TLRs and the downstream signaling pathways that are activated, as well as the dual role of TLRs in regulating antiviral effects and excessive inflammatory responses in patients with coronavirus disease 2019 (COVID-19). In addition, this article describes recent progress in the development of TLR immunomodulators including the agonists and antagonists, as vaccine adjuvants or agents used to treat hyperinflammatory responses during SARS-CoV-2 infection.

摘要

Toll样受体(TLRs)是识别严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病原体相关分子模式(PAMPs)的关键传感器,可激活先天免疫反应以清除入侵病毒。然而,免疫反应失调可能引发促炎细胞因子和趋化因子的过度产生,从而导致免疫介导的病理状况加剧。因此,正确理解SARS-CoV-2与TLR诱导的免疫反应之间的相互作用对于制定有效的预防和治疗策略非常重要。在本综述中,我们讨论了TLRs对SARS-CoV-2成分的识别以及激活的下游信号通路,以及TLRs在调节2019冠状病毒病(COVID-19)患者抗病毒作用和过度炎症反应中的双重作用。此外,本文还介绍了TLR免疫调节剂(包括激动剂和拮抗剂)作为疫苗佐剂或用于治疗SARS-CoV-2感染期间过度炎症反应的药物的最新研发进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b53/9271922/bdf101100673/fmicb-13-948770-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b53/9271922/bdf101100673/fmicb-13-948770-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b53/9271922/bdf101100673/fmicb-13-948770-g001.jpg

相似文献

1
Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019.Toll样受体信号通路在严重急性呼吸综合征冠状病毒2诱导的固有免疫反应中的作用以及Toll样受体免疫调节剂在2019冠状病毒病患者中的潜在应用价值
Front Microbiol. 2022 Jun 27;13:948770. doi: 10.3389/fmicb.2022.948770. eCollection 2022.
2
Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.通过TRIF的Toll样受体3信号传导有助于对严重急性呼吸综合征冠状病毒感染产生保护性先天免疫反应。
mBio. 2015 May 26;6(3):e00638-15. doi: 10.1128/mBio.00638-15.
3
An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.TLR 对 SARS-CoV-2 感染反应的最新研究进展概述及 TLR 激动剂作为 SARS-CoV-2 疫苗佐剂的潜力。
Viruses. 2021 Nov 18;13(11):2302. doi: 10.3390/v13112302.
4
TLRs: Innate Immune Sentries against SARS-CoV-2 Infection.TLRs:对抗 SARS-CoV-2 感染的先天免疫哨兵。
Int J Mol Sci. 2023 Apr 29;24(9):8065. doi: 10.3390/ijms24098065.
5
Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments.用于治疗新型冠状病毒肺炎的Toll样受体(TLRs)激动剂和拮抗剂
Front Pharmacol. 2022 Sep 7;13:989664. doi: 10.3389/fphar.2022.989664. eCollection 2022.
6
Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection.目前对 SARS-CoV-2 感染中 Toll 样受体先天控制的理解。
Viruses. 2021 Oct 22;13(11):2132. doi: 10.3390/v13112132.
7
Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach. Toll 样受体在 SARS-CoV-2 中的作用:一种治疗方法。
Int J Mol Sci. 2022 Sep 14;23(18):10716. doi: 10.3390/ijms231810716.
8
Innate immune recognition against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的天然免疫识别
Inflamm Regen. 2023 Jan 26;43(1):7. doi: 10.1186/s41232-023-00259-5.
9
In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.基于 SARS-CoV-2 刺突糖蛋白与 ACE-2 受体同源物和人类 TLR 相互作用的比较特征的计算机研究。
J Med Virol. 2020 Oct;92(10):2105-2113. doi: 10.1002/jmv.25987. Epub 2020 May 17.
10
Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity.新型冠状病毒肺炎感染中的血栓形成:血小板激活介导的免疫作用
Thromb J. 2021 Aug 23;19(1):59. doi: 10.1186/s12959-021-00311-9.

引用本文的文献

1
Role of the TLR signaling pathway in the pathogenesis of glioblastoma multiforme with an emphasis on immunotherapy.Toll样受体(TLR)信号通路在多形性胶质母细胞瘤发病机制中的作用,重点在于免疫治疗。
Biochem Biophys Rep. 2025 Jul 18;43:102149. doi: 10.1016/j.bbrep.2025.102149. eCollection 2025 Sep.
2
Patients Hospitalized with COVID-19 Demonstrate Distinct Plasma Cytokine and Chemokine Concentrations in vivo and TLR-Mediated Cytokine and Chemokine Production in Whole Blood in vitro.感染新冠病毒住院患者体内血浆细胞因子和趋化因子浓度各异,且体外全血中TLR介导的细胞因子和趋化因子产生情况也有所不同。
J Innate Immun. 2025;17(1):288-301. doi: 10.1159/000545432. Epub 2025 May 28.
3

本文引用的文献

1
Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.纳米颗粒递呈的 TLR4 和 RIG-I 激动剂增强了对 SARS-CoV-2 亚单位疫苗的免疫应答。
J Control Release. 2022 Jul;347:476-488. doi: 10.1016/j.jconrel.2022.05.023. Epub 2022 May 20.
2
High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens.高滴度中和抗体针对由 Alhydroxyquim-II 佐剂化三聚体刺突抗原诱导的 SARS-CoV-2 Delta 变异株。
Microbiol Spectr. 2022 Feb 23;10(1):e0169521. doi: 10.1128/spectrum.01695-21. Epub 2022 Feb 16.
3
Role of toll-like receptors in post-COVID-19 associated neurodegenerative disorders?
Toll样受体在新冠后相关神经退行性疾病中的作用?
Front Med (Lausanne). 2025 Mar 26;12:1458281. doi: 10.3389/fmed.2025.1458281. eCollection 2025.
4
Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.鼻内给药的TLR2/6激动剂INNA-051的评估:安全性、耐受性及药理学验证
ERJ Open Res. 2024 Dec 9;10(6). doi: 10.1183/23120541.00199-2024. eCollection 2024 Nov.
5
A systems biology approach unveils different gene expression control mechanisms governing the immune response genetic program in peripheral blood mononuclear cells exposed to SARS-CoV-2.一种系统生物学方法揭示了在暴露于SARS-CoV-2的外周血单核细胞中,控制免疫反应遗传程序的不同基因表达调控机制。
PLoS One. 2024 Dec 5;19(12):e0314754. doi: 10.1371/journal.pone.0314754. eCollection 2024.
6
Toll-like receptors polymorphisms and COVID-19: a systematic review.Toll样受体基因多态性与2019冠状病毒病:一项系统评价
Mol Cell Biochem. 2025 May;480(5):2677-2688. doi: 10.1007/s11010-024-05137-3. Epub 2024 Nov 9.
7
Variants rs3804099 and rs3804100 in the Gene Induce Different Profiles of TLR-2 Expression and Cytokines in Response to Spike of SARS-CoV-2.基因中的变体 rs3804099 和 rs3804100 导致针对 SARS-CoV-2 刺突的 TLR-2 表达和细胞因子产生不同的谱。
Int J Mol Sci. 2024 Oct 15;25(20):11063. doi: 10.3390/ijms252011063.
8
Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections.Toll样受体4(TLR4)与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的相互作用:揭示2019冠状病毒病(COVID-19)感染中炎症和严重程度的复杂机制
J Inflamm Res. 2024 Jul 26;17:5077-5091. doi: 10.2147/JIR.S474707. eCollection 2024.
9
Distinct Effects of Respiratory Viral Infection Models on miR-149-5p, IL-6 and p63 Expression in BEAS-2B and A549 Epithelial Cells.呼吸道病毒感染模型对 BEAS-2B 和 A549 上皮细胞中 miR-149-5p、IL-6 和 p63 表达的影响。
Cells. 2024 May 26;13(11):919. doi: 10.3390/cells13110919.
10
Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development.SARS-CoV-2 刺突蛋白的免疫表位及通用疫苗开发的考虑因素。
Immunohorizons. 2024 Mar 1;8(3):214-226. doi: 10.4049/immunohorizons.2400003.
MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern.
MPLA 佐剂化脂质体包裹 S-三聚体或 RBD 或 S1,但不包裹 S-ECD,可诱导针对 SARS-CoV-2 及其关注变体的强大中和作用。
J Med Chem. 2022 Feb 24;65(4):3563-3574. doi: 10.1021/acs.jmedchem.1c02025. Epub 2022 Feb 2.
4
SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties.SARS-CoV-2 刺突 S1 亚单位诱导神经炎症、小胶质细胞和行为性疾病反应:模式识别受体样特性的证据。
Brain Behav Immun. 2022 Feb;100:267-277. doi: 10.1016/j.bbi.2021.12.007. Epub 2021 Dec 13.
5
Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19.作用于Toll样受体(TLR)7和/或TLR8的药物制剂在2019冠状病毒病(COVID-19)中的潜在价值
Curr Res Pharmacol Drug Discov. 2021;2:100068. doi: 10.1016/j.crphar.2021.100068. Epub 2021 Nov 2.
6
SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway.SARS-CoV-2 刺突蛋白通过 TLR2 依赖性激活 NF-κB 途径诱导炎症反应。
Elife. 2021 Dec 6;10:e68563. doi: 10.7554/eLife.68563.
7
An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.TLR 对 SARS-CoV-2 感染反应的最新研究进展概述及 TLR 激动剂作为 SARS-CoV-2 疫苗佐剂的潜力。
Viruses. 2021 Nov 18;13(11):2302. doi: 10.3390/v13112302.
8
Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection.目前对 SARS-CoV-2 感染中 Toll 样受体先天控制的理解。
Viruses. 2021 Oct 22;13(11):2132. doi: 10.3390/v13112132.
9
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity.一种用于诱导 SARS-CoV-2 T 细胞免疫的 COVID-19 肽疫苗。
Nature. 2022 Jan;601(7894):617-622. doi: 10.1038/s41586-021-04232-5. Epub 2021 Nov 23.
10
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.对由PIKA佐剂的S三聚体新冠疫苗的快速且持久的免疫反应。
Mol Biomed. 2021;2(1):29. doi: 10.1186/s43556-021-00054-z. Epub 2021 Sep 27.